Navigation Links
HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing
Date:7/28/2010

SEATTLE, July 28 /PRNewswire/ -- HemaQuest Pharmaceuticals, a clinical stage biotechnology company developing small molecule therapeutics for sickle cell disease, beta thalassemia and EBV-related cancers, announced today the closing of an additional $4M to its Series B financing by new investor, Latterell Venture Partners. This investment brings the total Series B financing to $16M. The financing is intended to help advance HemaQuest's two lead products, HQK-1001 and HQK-1004, through Phase 2b clinical trials. Latterell Venture Partners joins the HemaQuest investor syndicate which includes Aberdare Ventures, De Novo Ventures, Forward Ventures and Lilly Ventures. In conjunction with the financing, James Woody, MD, PhD, General Partner at Latterell Venture Partners, has joined HemaQuest's Board of Directors.

"HemaQuest is focusing on much needed clinical therapies for serious and life threatening orphan diseases. As a clinician who has cared for such patients, it is clear the unmet need is large and there is a significant need for novel new medications," said Dr. Woody. "The company, with excellent leadership and considerable skill in the hematology and oncology space, has made great progress with the two lead compounds, with promising results in early clinical trials. We look forward to working closely with our colleagues at HemaQuest to advance these important drugs into registration trials, and eventually to patients."

Fred Dotzler, Managing Director of De Novo Ventures and HemaQuest's Chairman of the Board, said, "The investment by Latterell Venture Partners provides further validation to the Company's technologies and progress in developing programs for its two lead products.  We are delighted to have the very talented Jim Woody join the Board of Directors."

ABOUT HEMAQUEST PHARMACEUTICALS

HemaQuest Pharmaceuticals (www.HemaQuest.com) is a Seattle-based biopharmaceutical company focused on developing small molecule therapeutics based on its proprietary short chain fatty acid technologies to treat orphan hematologic diseases. HQK-1001 is an orally administered small molecule therapeutic being developed to treat the two most common hemoglobin disorders, sickle cell disease and beta thalassemia. The drug candidate has advanced through Phase 1 clinical trials and is completing testing in proof of concept clinical studies in patients with sickle cell disease and beta thalassemia. HQK-1004 is a unique therapy designed to treat malignancies associated with Epstein-Barr virus. A Phase 2 clinical trial is being initiated with this drug candidate.

CONTACT:  Jerome Lyons, Office Manager   T: 206.826.9900   jlyons@hemaquest.com


'/>"/>
SOURCE HemaQuest Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amylin Pharmaceuticals to Present at the Wedbush Life Sciences Conference 2010
2. Foundation Venture Capital Group Sells Interest in Longevica Pharmaceuticals
3. Onyx Pharmaceuticals Announces Positive Top-Line Carfilzomib Data From Phase 2b Study
4. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide a Clinical Update on Carfilzomib
5. Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
6. Poniard Pharmaceuticals Receives NASDAQ Deficiency Notice Related to Minimum Bid Price
7. Bayer HealthCare Pharmaceuticals Supports New Jersey Governors School in the Sciences at Drew University
8. Anadys Pharmaceuticals to Report Second Quarter 2010 Financial Results
9. Lotus Pharmaceuticals Terminates SEDA
10. Ampio Pharmaceuticals Announces Initiation of Phase II Clinical Trial of Optinaâ„¢
11. China Yongxin Pharmaceuticals Inc. Announces the Expansion of Its Chain of Retail Stores to 110 Stores
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... , June 6, 2017  Diplomat Specialty Infusion Group, a brand ... environment to its Iowa location. ... now features an ISO 7 cleanroom—the standard needed to ... with a low level of pollutants. ... nutrition consumers and better serve our Iowa ...
(Date:6/1/2017)... 2017 Nutriceutical Holdings (NH), parent company of ... and KD Pharma Group have decided to join forces ... Pharma Group. KD Pharma Group will become the largest ... the entire company. "We believe we have ... to growing the NH companies by providing us with ...
(Date:5/26/2017)... International plc (NASDAQ: ENDP ) announced today that ... Company in a fireside chat at Goldman Sachs, 38 th ... at 10:40 a.m. PT / 1:40 p.m. ET. The conference ... Palos Verdes, CA. A live webcast ... the Company,s website at http://www.endo.com/investors/overview . Participants should allow ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... , ... 21 Middle East and South Asia Leaders Selected as Eisenhower Fellows ... and civil society in 11 countries across the Middle East and South Asia to ... exchange of knowledge and ideas with the leading minds in their fields. , ...
(Date:6/23/2017)... ... , ... PureLife Dental is pleased to announce that California Dental Association (CDA) ... of the amalgam separator endorsement, all CDA members may purchase an ECO II amalgam ... value. This partnership between PureLife and CDA is especially timely as it coincides with ...
(Date:6/23/2017)... ... June 23, 2017 , ... American Farmer, will feature Chr. Hansen, Inc (CHR ... air fourth quarter 2017. American Farmer airs Tuesdays at 8:30aET on RFD-TV. Check your ... Chr. Hansen in Denmark in 1874 after a groundbreaking discovery of how to industrialize ...
(Date:6/23/2017)... , ... June 23, 2017 , ... ... financial planning, and related services to families and business owners in and around ... drive to benefit senior citizens in the area. , Meals on Wheels of ...
(Date:6/23/2017)... Gilmer, TX (PRWEB) , ... June 23, 2017 , ... ... consultations to residential and business clients throughout eastern Texas, is announcing the launch of ... , Recent breast cancer statistics in the United States reveal that an estimated ...
Breaking Medicine News(10 mins):